 Liyen Loh
Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mucosal-Associated Invariant T Cells | 12 | 2024 | 27 | 2.760 |
Why?
| | CD8-Positive T-Lymphocytes | 19 | 2023 | 824 | 2.190 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 13 | 2014 | 83 | 1.840 |
Why?
| | Simian Immunodeficiency Virus | 12 | 2014 | 85 | 1.790 |
Why?
| | Influenza, Human | 15 | 2024 | 603 | 1.620 |
Why?
| | Influenza A virus | 10 | 2022 | 104 | 1.490 |
Why?
| | Killer Cells, Natural | 6 | 2024 | 422 | 1.250 |
Why?
| | Influenza A Virus, H7N9 Subtype | 5 | 2018 | 5 | 0.950 |
Why?
| | Leukocytes, Mononuclear | 7 | 2022 | 543 | 0.860 |
Why?
| | Immunity, Innate | 3 | 2024 | 802 | 0.810 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 4 | 2023 | 330 | 0.800 |
Why?
| | Alleles | 2 | 2024 | 847 | 0.790 |
Why?
| | Coculture Techniques | 2 | 2020 | 217 | 0.760 |
Why?
| | Gene Products, gag | 6 | 2012 | 36 | 0.730 |
Why?
| | Epitopes, T-Lymphocyte | 7 | 2022 | 185 | 0.730 |
Why?
| | Alveolar Epithelial Cells | 1 | 2020 | 106 | 0.620 |
Why?
| | Phenotype | 3 | 2024 | 3059 | 0.550 |
Why?
| | Thymus Gland | 4 | 2024 | 303 | 0.550 |
Why?
| | Immunity, Mucosal | 1 | 2016 | 87 | 0.500 |
Why?
| | Immunologic Memory | 6 | 2020 | 335 | 0.490 |
Why?
| | Macaca nemestrina | 13 | 2014 | 29 | 0.490 |
Why?
| | Interleukin-18 | 1 | 2016 | 239 | 0.480 |
Why?
| | HLA-A24 Antigen | 2 | 2024 | 6 | 0.430 |
Why?
| | Histocompatibility Antigens Class I | 5 | 2024 | 196 | 0.400 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2010 | 166 | 0.380 |
Why?
| | Australia | 5 | 2024 | 247 | 0.370 |
Why?
| | Pneumonia, Viral | 1 | 2016 | 361 | 0.370 |
Why?
| | Natural Killer T-Cells | 2 | 2022 | 64 | 0.360 |
Why?
| | T-Lymphocyte Subsets | 4 | 2024 | 410 | 0.340 |
Why?
| | Cell Differentiation | 4 | 2024 | 1854 | 0.340 |
Why?
| | Single-Cell Analysis | 2 | 2024 | 265 | 0.340 |
Why?
| | Immunophenotyping | 4 | 2020 | 310 | 0.340 |
Why?
| | Immunity, Cellular | 3 | 2018 | 266 | 0.320 |
Why?
| | T-Lymphocytes, Helper-Inducer | 2 | 2021 | 137 | 0.310 |
Why?
| | Genes, gag | 1 | 2008 | 4 | 0.310 |
Why?
| | CD4-Positive T-Lymphocytes | 7 | 2021 | 1040 | 0.310 |
Why?
| | Viruses | 2 | 2020 | 99 | 0.310 |
Why?
| | Granzymes | 2 | 2020 | 47 | 0.300 |
Why?
| | Lymphocyte Activation | 5 | 2020 | 1091 | 0.290 |
Why?
| | Interferon-gamma | 4 | 2020 | 759 | 0.280 |
Why?
| | T-Lymphocytes | 5 | 2024 | 1905 | 0.270 |
Why?
| | Mutation | 6 | 2014 | 3671 | 0.270 |
Why?
| | Cell Communication | 2 | 2020 | 292 | 0.260 |
Why?
| | Receptors, Antigen, T-Cell | 5 | 2024 | 699 | 0.260 |
Why?
| | Immunotherapy | 5 | 2024 | 579 | 0.260 |
Why?
| | Animals | 24 | 2024 | 34628 | 0.250 |
Why?
| | Cytokines | 4 | 2021 | 1995 | 0.240 |
Why?
| | Monocytes | 2 | 2020 | 553 | 0.240 |
Why?
| | Oceania | 1 | 2024 | 4 | 0.240 |
Why?
| | Receptors, KIR3DL1 | 1 | 2024 | 17 | 0.240 |
Why?
| | Vaccination | 5 | 2021 | 1350 | 0.230 |
Why?
| | Aging | 3 | 2020 | 1767 | 0.230 |
Why?
| | Blood | 2 | 2019 | 99 | 0.230 |
Why?
| | B-Lymphocytes | 2 | 2021 | 813 | 0.230 |
Why?
| | Anus Neoplasms | 1 | 2024 | 30 | 0.220 |
Why?
| | Viral Load | 4 | 2024 | 448 | 0.220 |
Why?
| | Humans | 35 | 2024 | 128896 | 0.220 |
Why?
| | Mice, Inbred C57BL | 6 | 2024 | 5270 | 0.220 |
Why?
| | Virus Replication | 4 | 2024 | 448 | 0.210 |
Why?
| | Rectal Neoplasms | 1 | 2024 | 135 | 0.210 |
Why?
| | Viremia | 3 | 2008 | 133 | 0.200 |
Why?
| | Orthomyxoviridae Infections | 2 | 2024 | 65 | 0.200 |
Why?
| | Selection, Genetic | 1 | 2024 | 250 | 0.200 |
Why?
| | Hematologic Neoplasms | 1 | 2024 | 141 | 0.190 |
Why?
| | Influenza Vaccines | 3 | 2022 | 544 | 0.190 |
Why?
| | DNA, Viral | 2 | 2014 | 380 | 0.180 |
Why?
| | Forkhead Box Protein O1 | 1 | 2021 | 20 | 0.180 |
Why?
| | Immunodominant Epitopes | 1 | 2020 | 28 | 0.180 |
Why?
| | HLA-B27 Antigen | 1 | 2020 | 15 | 0.180 |
Why?
| | Cells, Cultured | 4 | 2021 | 4048 | 0.170 |
Why?
| | Cellular Senescence | 2 | 2021 | 176 | 0.170 |
Why?
| | Lysosomal-Associated Membrane Protein 1 | 1 | 2020 | 6 | 0.170 |
Why?
| | Antibody Formation | 1 | 2021 | 284 | 0.170 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 85 | 0.160 |
Why?
| | Genetic Variation | 1 | 2024 | 935 | 0.160 |
Why?
| | Proviruses | 1 | 2019 | 12 | 0.160 |
Why?
| | HTLV-I Infections | 1 | 2019 | 22 | 0.160 |
Why?
| | HLA-B37 Antigen | 1 | 2018 | 1 | 0.160 |
Why?
| | HLA-A1 Antigen | 1 | 2018 | 4 | 0.160 |
Why?
| | Human T-lymphotropic virus 1 | 1 | 2019 | 28 | 0.160 |
Why?
| | SAIDS Vaccines | 2 | 2009 | 4 | 0.160 |
Why?
| | Mice | 7 | 2024 | 16543 | 0.150 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2019 | 51 | 0.150 |
Why?
| | Clonal Selection, Antigen-Mediated | 1 | 2018 | 3 | 0.150 |
Why?
| | Antibodies, Viral | 4 | 2018 | 598 | 0.150 |
Why?
| | Extracellular Vesicles | 1 | 2020 | 123 | 0.150 |
Why?
| | Respiratory System | 1 | 2019 | 153 | 0.140 |
Why?
| | HIV Infections | 4 | 2014 | 2696 | 0.140 |
Why?
| | Virus Diseases | 1 | 2020 | 207 | 0.140 |
Why?
| | Cross Reactions | 2 | 2014 | 129 | 0.140 |
Why?
| | Melanoma | 1 | 2024 | 735 | 0.140 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily B | 1 | 2016 | 11 | 0.130 |
Why?
| | Survival Analysis | 2 | 2018 | 1282 | 0.130 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 348 | 0.130 |
Why?
| | A549 Cells | 1 | 2016 | 61 | 0.130 |
Why?
| | Skin Neoplasms | 1 | 2024 | 828 | 0.130 |
Why?
| | Multiple Myeloma | 1 | 2018 | 120 | 0.130 |
Why?
| | RNA, Viral | 2 | 2012 | 622 | 0.130 |
Why?
| | Hypersensitivity | 1 | 2020 | 277 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 957 | 0.130 |
Why?
| | Minor Histocompatibility Antigens | 3 | 2022 | 45 | 0.130 |
Why?
| | Escherichia coli | 1 | 2020 | 782 | 0.130 |
Why?
| | AIDS Vaccines | 3 | 2010 | 47 | 0.120 |
Why?
| | Influenza A Virus, H1N1 Subtype | 2 | 2014 | 145 | 0.120 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2020 | 1204 | 0.120 |
Why?
| | HIV Antibodies | 1 | 2014 | 58 | 0.120 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 2014 | 20 | 0.120 |
Why?
| | Adult | 10 | 2021 | 35361 | 0.110 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2014 | 131 | 0.110 |
Why?
| | Aged | 7 | 2021 | 22035 | 0.110 |
Why?
| | Cell Line, Tumor | 1 | 2020 | 3100 | 0.100 |
Why?
| | Transcriptome | 1 | 2018 | 871 | 0.100 |
Why?
| | Influenza B virus | 2 | 2022 | 37 | 0.090 |
Why?
| | Middle Aged | 7 | 2021 | 30977 | 0.090 |
Why?
| | Genetic Engineering | 2 | 2009 | 89 | 0.090 |
Why?
| | Gene Expression | 1 | 2016 | 1476 | 0.090 |
Why?
| | Male | 11 | 2024 | 63146 | 0.090 |
Why?
| | HIV-1 | 2 | 2014 | 840 | 0.080 |
Why?
| | Mice, Knockout | 3 | 2024 | 2770 | 0.080 |
Why?
| | HIV | 2 | 2009 | 223 | 0.080 |
Why?
| | Neoplasms | 1 | 2024 | 2426 | 0.080 |
Why?
| | Female | 10 | 2024 | 68162 | 0.080 |
Why?
| | Adoptive Transfer | 2 | 2020 | 217 | 0.080 |
Why?
| | HLA-A Antigens | 2 | 2022 | 53 | 0.080 |
Why?
| | Gene Expression Regulation | 3 | 2018 | 2520 | 0.080 |
Why?
| | Young Adult | 6 | 2021 | 12286 | 0.080 |
Why?
| | Disease Models, Animal | 4 | 2020 | 3994 | 0.070 |
Why?
| | Replicon | 1 | 2008 | 14 | 0.070 |
Why?
| | West Nile virus | 1 | 2008 | 38 | 0.070 |
Why?
| | Vaccines, Synthetic | 1 | 2008 | 129 | 0.070 |
Why?
| | Models, Biological | 1 | 2014 | 1702 | 0.070 |
Why?
| | Oligopeptides | 1 | 2008 | 256 | 0.070 |
Why?
| | Molecular Sequence Data | 2 | 2008 | 2842 | 0.070 |
Why?
| | Hemagglutinin Glycoproteins, Influenza Virus | 2 | 2018 | 23 | 0.060 |
Why?
| | Peptides | 3 | 2022 | 902 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1045 | 0.060 |
Why?
| | Acute Disease | 1 | 2008 | 978 | 0.060 |
Why?
| | Carboxylic Ester Hydrolases | 1 | 2024 | 19 | 0.060 |
Why?
| | Cohort Studies | 3 | 2021 | 5394 | 0.060 |
Why?
| | Oleic Acid | 1 | 2024 | 38 | 0.060 |
Why?
| | Base Sequence | 1 | 2008 | 2157 | 0.060 |
Why?
| | Signal Transduction | 1 | 2016 | 4857 | 0.050 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2024 | 117 | 0.050 |
Why?
| | Immunoglobulins | 1 | 2023 | 158 | 0.050 |
Why?
| | Receptors, KIR | 1 | 2023 | 96 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2021 | 7050 | 0.050 |
Why?
| | Amino Acid Sequence | 2 | 2021 | 2047 | 0.050 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1694 | 0.050 |
Why?
| | Cell Proliferation | 2 | 2020 | 2337 | 0.050 |
Why?
| | Chronic Disease | 1 | 2008 | 1715 | 0.050 |
Why?
| | Ligands | 1 | 2023 | 614 | 0.050 |
Why?
| | Mucous Membrane | 1 | 2022 | 122 | 0.050 |
Why?
| | Thymocytes | 1 | 2020 | 30 | 0.040 |
Why?
| | Time Factors | 2 | 2010 | 6568 | 0.040 |
Why?
| | Haloperidol | 1 | 2020 | 36 | 0.040 |
Why?
| | Viral Plaque Assay | 1 | 2020 | 29 | 0.040 |
Why?
| | Dogs | 1 | 2021 | 372 | 0.040 |
Why?
| | Respiratory Tract Infections | 1 | 2024 | 372 | 0.040 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2020 | 142 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 588 | 0.040 |
Why?
| | Hospitalization | 2 | 2021 | 2080 | 0.040 |
Why?
| | Gene Frequency | 1 | 2021 | 503 | 0.040 |
Why?
| | Exudates and Transudates | 1 | 2019 | 12 | 0.040 |
Why?
| | Antigen Presentation | 1 | 2020 | 203 | 0.040 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 182 | 0.040 |
Why?
| | Lung | 2 | 2024 | 3925 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2020 | 422 | 0.040 |
Why?
| | Antibody-Producing Cells | 1 | 2018 | 30 | 0.040 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2018 | 38 | 0.040 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2018 | 28 | 0.040 |
Why?
| | Thalidomide | 1 | 2018 | 30 | 0.040 |
Why?
| | Vaccines, Inactivated | 1 | 2018 | 69 | 0.040 |
Why?
| | Cellular Microenvironment | 1 | 2018 | 79 | 0.040 |
Why?
| | Phylogeny | 1 | 2021 | 843 | 0.030 |
Why?
| | HLA-DR Antigens | 1 | 2018 | 226 | 0.030 |
Why?
| | Lymphoid Progenitor Cells | 1 | 2016 | 11 | 0.030 |
Why?
| | Macrophages | 1 | 2024 | 1452 | 0.030 |
Why?
| | Antigens, CD1d | 1 | 2016 | 66 | 0.030 |
Why?
| | Allergens | 1 | 2020 | 463 | 0.030 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 225 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2021 | 2073 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2019 | 1146 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2018 | 465 | 0.030 |
Why?
| | Receptors, KIR2DL1 | 1 | 2015 | 18 | 0.030 |
Why?
| | Antigens, CD | 1 | 2018 | 479 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2018 | 428 | 0.030 |
Why?
| | Hemagglutination Tests | 1 | 2014 | 7 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2020 | 708 | 0.030 |
Why?
| | Mitochondria | 1 | 2020 | 837 | 0.030 |
Why?
| | Likelihood Functions | 1 | 2014 | 135 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2020 | 1423 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 772 | 0.030 |
Why?
| | Crystallography, X-Ray | 1 | 2014 | 436 | 0.020 |
Why?
| | HLA Antigens | 1 | 2014 | 236 | 0.020 |
Why?
| | Critical Illness | 1 | 2018 | 753 | 0.020 |
Why?
| | Age Factors | 1 | 2017 | 3133 | 0.020 |
Why?
| | MicroRNAs | 1 | 2016 | 668 | 0.020 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2009 | 43 | 0.020 |
Why?
| | Receptors, OX40 | 1 | 2008 | 15 | 0.020 |
Why?
| | Fusion Proteins, gag-pol | 1 | 2008 | 2 | 0.020 |
Why?
| | Viral Vaccines | 1 | 2008 | 93 | 0.020 |
Why?
| | Blood Component Transfusion | 1 | 2008 | 80 | 0.020 |
Why?
| | Random Allocation | 1 | 2008 | 351 | 0.020 |
Why?
| | Models, Animal | 1 | 2009 | 370 | 0.020 |
Why?
| | Longevity | 1 | 2008 | 150 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2008 | 513 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2008 | 778 | 0.020 |
Why?
| | Biomarkers | 1 | 2016 | 3874 | 0.020 |
Why?
| | Child | 1 | 2024 | 20824 | 0.010 |
Why?
| | Cell Line | 1 | 2009 | 2759 | 0.010 |
Why?
| | Adolescent | 1 | 2019 | 20197 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2008 | 10239 | 0.010 |
Why?
|
|
Loh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|